Literature DB >> 17977604

Grouping of patients with common variable immunodeficiency based on immunoglobulin biosynthesis: comparison with a classification system on CD4-naïve cells.

Olga Livaditi1, Evangelos J Giamarellos-Bourboulis, Iotaoannis Kakkas, Violetta Kapsimali, Peggy Lymberi, Chryssa Papastariades, Emmanuel E Douzinas.   

Abstract

The present study compared two different systems of classification of patients with common variable immunodeficiency (CVID); one based on in vitro immunoglobulin biosynthesis; and another on CD4-naïve cell counts. Peripheral blood mononuclear cells (PBMCs) were isolated from 35 patients with CVID and 20 healthy controls. They were stimulated for the secretion of IgM and IgG after stimulation with Staphylococcus aureus Cowan I (SAC) upon supplementation of interleukin-2 (IL-2) or with pokeweed mitogen. T cell subsets were estimated by flow cytometry. By the first system, patients were classified into group A (n=18) with secretion of neither IgG nor IgM; into group B (n=12) with detectable IgM but no IgG secretion; and into group C (n=5) with IgM and IgG secretion similar to controls. By the second system, patients were classified into group I (n=12) with less than 109 CD4-naïve cells/mul; into group II (n=12) with CD4-naïve cells within 109-225microl(-1); and into group III (n=11) with more than 225 CD4-naïve cells/mul. All groups I-III were defective for in vitro release of IgG and IgM. The likelihood ratio for splenomegaly in patients with <225 CD4-naïve cells/mul was 5.08 (p: 0.024). CD4-naïve cell counts of patients were positively correlated to serum levels of IgG and IgA of patients. The presented results revealed that the former system described adequately the function of B cells and the latter the clinical status of the patient. Our proposal is that both should be used for the characterization of patients with CVID.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17977604     DOI: 10.1016/j.imlet.2007.09.006

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  5 in total

1.  B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease.

Authors:  Gaël Mouillot; Maryvonnick Carmagnat; Laurence Gérard; Jean-Luc Garnier; Claire Fieschi; Nicolas Vince; Lionel Karlin; Jean-François Viallard; Roland Jaussaud; Julien Boileau; Jean Donadieu; Martine Gardembas; Nicolas Schleinitz; Felipe Suarez; Eric Hachulla; Karen Delavigne; Martine Morisset; Serge Jacquot; Nicolas Just; Lionel Galicier; Dominique Charron; Patrice Debré; Eric Oksenhendler; Claire Rabian
Journal:  J Clin Immunol       Date:  2010-05-01       Impact factor: 8.317

2.  Skewed distribution of circulating activated natural killer T (NKT) cells in patients with common variable immunodeficiency disorders (CVID).

Authors:  Karina I Carvalho; Karina M Melo; Fernanda R Bruno; Jennifer E Snyder-Cappione; Douglas F Nixon; Beatriz T Costa-Carvalho; Esper G Kallas
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

3.  Circulating phenotypic B-1 cells are decreased in common variable immunodeficiency and correlate with immunoglobulin M levels.

Authors:  K Kraljevic; S Wong; D A Fulcher
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

Review 4.  Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions.

Authors:  Helen Chapel; Charlotte Cunningham-Rundles
Journal:  Br J Haematol       Date:  2009-03-30       Impact factor: 6.998

5.  Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome.

Authors:  Evangelos J Giamarellos-Bourboulis; Efterpi Apostolidou; Malvina Lada; Ioannis Perdios; Nikolaos K Gatselis; Iraklis Tsangaris; Marianna Georgitsi; Magdalini Bristianou; Theodora Kanni; Kalliopi Sereti; Miltiades A Kyprianou; Anastasia Kotanidou; Apostolos Armaganidis
Journal:  Crit Care       Date:  2013-10-21       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.